Webinar - Rapid identification and characterisation of Affimer technology

Affinity_and_specificity_cropped-1

This webinar recording features a presentation by Avacta Life Sciences' Chief Technology Officer Dr Matt Johnson. In it, he discusses Affimer® technology, a novel antibody mimetic and powerful antibody alternative. Plus:

  • Why Affimer technology has a number of key benefits over other affinity reagents.
  • How Avacta uses the IntelliCyt iQue device in its screening process.
  • A case study using Affimer technology to inhibit PD-L1, an immune check point protein expressed by tumor cells to trick t-cells into not destroying them. 

Enter your details to access the webinar.

 

"Using Affimer technology we have been able to demonstrate effective label free electrochemical immunoassays. The performance has exceeded that associated with comparable antibodies”

Professor Jason J Davis, Department of Chemistry, University of Oxford, and Dr Lee's Reader in Chemistry, Christ Church College, Oxford.